Results 21 to 30 of about 3,046 (215)

Novel Use of Mavacamten in RAF1-Associated Noonan Syndrome With Hypertrophic Cardiomyopathy [PDF]

JACC: Case Reports
Background: Mavacamten is a first-in class allosteric inhibitor of cardiac myosin that is shown to reduce left ventricular outflow tract obstruction and improves symptoms in obstructive hypertrophic cardiomyopathy (HCM).
Lubna Ziauddin, MD, Erin Davidson, PharmD, Hannah Spears, MS, PA-C, Erin Coffman, CGC, Markey McNutt, MD, PhD, Nicholas Hendren, MD, Katherine Kearney, MBBS, PhD, Sheila M. Hegde, MD, MPH, Justin L. Grodin, MD, MPH, Natalie Tapaskar, MD   +9 more
doaj   +2 more sources

Real-World Experience With Mavacamten in SRT-Eligible Obstructive HCM [PDF]

JACC: Advances
Background: Mavacamten, a cardiac myosin inhibitor, has been shown to improve symptoms and reduce left ventricular outflow tract gradients in obstructive hypertrophic cardiomyopathy (oHCM). However, real-world data regarding longer-term clinical outcomes,
Lusha W. Liang, MD, MS, Hiroo Takayama, MD, PhD, Tamim M. Nazif, MD, Linda Gojcaj, PA-C, Yuichi J. Shimada, MD, MPH, Shepard D. Weiner, MD   +5 more
doaj   +2 more sources

Mavacamten: First Approval

Drugs, 2022
Mavacamten (Camzyos™) is an oral small-molecule cardiac myosin inhibitor developed by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of diastolic dysfunction. In April 2022, mavacamten was approved for use in the USA in the treatment of adults with symptomatic New ...
Susan Keam (4873372)
openaire   +3 more sources

Long‐Term Efficacy and Safety of Mavacamten in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy: Week 78 Results From the EXPLORER‐CN Study [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Long‐term efficacy and safety of mavacamten in Chinese patients with obstructive hypertrophic cardiomyopathy are unknown. Methods Patients who completed the 30‐week, double‐blind, placebo‐controlled treatment period in EXPLORER‐CN (A Study to ...
Zhuang Tian, Xiaoyan Li, Liwen Li, Qing Zhang, Jian’an Wang, Yunqi Shi, Daoquan Peng, Wei Ma, Ping Yang, Xiang Cheng, Wei Jin, Fang Wang, Yimeng Xie, Beth Pan, Victoria Florea, Shuyang Zhang   +15 more
doaj   +2 more sources

Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Patient-Reported Health Status Analysis up to 78 Weeks in the EXPLORER-CN Study [PDF]

Cardiology and Therapy
Introduction Improvement of symptoms, physical function, and quality of life is one treatment goal for patients with obstructive hypertrophic cardiomyopathy (HCM).
Zhuang Tian, Xiaoyan Li, Liwen Li, Qing Zhang, Jian’an Wang, Yunqi Shi, Daoquan Peng, Wei Ma, Ping Yang, Xiang Cheng, Wei Jin, Fang Wang, Arteid Memaj, Yimeng Xie, Beth Pan, Victoria Florea, Jing Zheng, Yue Zhong, Shuyang Zhang   +18 more
doaj   +2 more sources

Comparison of Diastolic Function Parameters After Alcohol Septal Ablation and Mavacamten Therapy in Obstructive Hypertrophic Cardiomyopathy

Journal of Cardiovascular Development and Disease
Cardiac myosin inhibitors have been shown to improve diastolic function in patients with obstructive hypertrophic cardiomyopathy (HCM). Comparative studies to evaluate the diastolic effects of mavacamten versus alcohol septal ablation (ASA) have yet to ...
Danish Saleh, Ellis Y. Kim, Kifah Hussain, Ashraf Samhan, Meilynn Shi, Zhiying Meng, Elizabeth Schormann, Parmeen Bindra, Baljash Cheema, Dominic E. Fullenkamp, Abigail S. Baldridge, Jyothy J. Puthumana, Vera H. Rigolin, Paul C. Cremer, James D. Flaherty, Lubna Choudhury   +15 more
doaj   +2 more sources

Mavacamten alleviates sepsis-induced acute respiratory distress syndrome by modulating the PI3K/AKT/autophagy axis: a spatial transcriptomic-guided investigation [PDF]

Journal of Translational Medicine
Background Sepsis-induced acute respiratory distress syndrome (ARDS) is a life-threatening inflammatory lung condition with high mortality and no specific pharmacological treatments. The complex spatial heterogeneity of the lung during sepsis hinders the
Huaiyu Chen, Shaowu He, Lili Chen, Yi Zhang, Xiaoyan Guo, Yijun Lin, Xinsheng Ren, Wei Li, Mingrui Lin, Zhiqing Shen   +9 more
doaj   +2 more sources

Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The phase 2 PIONEER‐HCM (Phase 2 Open‐label Pilot Study Evaluating Mavacamten in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction) study showed that mavacamten improved left ventricular ...
Ahmad Masri, Steven J. Lester, John C. Stendahl, Sheila M. Hegde, Amy J. Sehnert, Ganesh Balaratnam, Ashish Shah, Shawna Fox, Andrew Wang   +8 more
doaj   +2 more sources

Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy [PDF]

European Heart Journal
Background and Aims Long-term safety and efficacy of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) are unknown. MAVA-LTE (NCT03723655) is an ongoing, 5-year, open-label extension study designed to evaluate the long-term ...
P. García-Pavía, A. Oręziak, A. Masri, R. Barriales-Villa, T. Abraham, A. Owens, M. Jensen, Wojciech Wojakowski, Tim Seidler, A. Hagège, N. Lakdawala, Andrew Wang, M. Wheeler, L. Choudhury, G. Balaratnam, A. Shah, S. Fox, S. Hegde, I. Olivotto   +18 more
semanticscholar   +4 more sources

Mavacamten in Obstructive Hypertrophic Cardiomyopathy: National Insights on Access and Safety Profile From Real‐World Data [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy, but real‐world prescription patterns, safety profile, and the effect of atrial fibrillation (AF) on outcomes remain unclear. Methods An observational multicenter analysis
Ayman R. Fath, Amro Aglan, Srihari S. Naidu, Michael J. Mader, Robert J. Chilton, Islam Y. Elgendy, Martin S. Maron, Ethan J. Rowin   +7 more
doaj   +2 more sources